BMB Reports 2020; 53(1): 10-19  https://doi.org/10.5483/BMBRep.2020.53.1.309
Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review
Jong-Chan Park#, Sun-Ho Han# & Inhee Mook-Jung*
Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea
Correspondence to: Tel: +82-2-740-8245; Fax: +82-2-3672-7352; E-mail: inhee@snu.ac.kr
#These authors contributed equally to this work.
Received: December 1, 2019; Published online: January 31, 2020.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The AD pathophysiology entails chronic inflammation involving innate immune cells including microglia, astrocytes, and other peripheral blood cells. Inflammatory mediators such as cytokines and complements are also linked to AD pathogenesis. Despite increasing evidence supporting the association between abnormal inflammation and AD, no well-established inflammatory biomarkers are currently available for AD. Since many reports have shown that abnormal inflammation precedes the outbreak of the disease, non-invasive and readily available peripheral inflammatory biomarkers should be considered as possible biomarkers for early diagnosis of AD. In this mini-review, we introduce the peripheral biomarker candidates related to abnormal inflammation in AD and discuss their possible molecular mechanisms. Furthermore, we also summarize the current state of inflammatory biomarker research in clinical practice and molecular diagnostics. We believe this review will provide new insights into biomarker candidates for the early diagnosis of AD with systemic relevance to inflammation during AD pathogenesis.

Keywords: Alzheimer's disease, Cytokine, Immune Cell, Inflammation, Peripheral blood biomarker
INTRODUCTION

Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases with progressive and irreversible pathogenesis. Numerous studies have suggested that AD pathogenesis is associated with not only abnormal cerebral function but also changes in central and peripheral immune system. Specifically, it is characterized by neuroinflammation (1, 2). Activated microglia are one of the early hallmarks of AD pathogenesis (3). Numerous reports have shown over-activation of microglia (4, 5), activated complement system (6), increased production of cytokines (7) and chemokines during AD pathogenesis, and some of them were suggested as diagnostic biomarkers (8, 9). Recently, immune-related pathophysiological mechanisms were discovered during AD pathogenesis, including innate immune cell infiltration and altered brain-gut axis as well as microglial and astrocyte activation (10, 11) which play a role in peripheral immune dynamics and act as possible biomarkers for disease.

Various inflammatory molecules are affected by AD pathogenesis, with abnormal levels in different brain regions (12, 13). Amyloid beta (Aβ) and amyloid precursor protein (APP) induce cytokine and chemokine release from microglia, astrocytes, and neurons; chemokine and cytokines also promote the expression and deposition of amyloid beta, which activates the vicious cycle (14). Furthermore, neuroinflammation may be an early event and plays a critical role in tau pathology, characterized by microglial activation preceding tau tangle formation. Immunosuppression ameliorated tau pathology in P301S transgenic mice (15). Also, peripheral levels of inflammation-related cytokines change during AD pathogenesis and are significantly correlated with disease progression (1618). Therefore, the crosstalk between abnormal events in the central compartment, involving neuronal dysfunction and microglial activation, and peripheral immune system is critical for the understanding of the mechanism of AD pathogenesis (19).

In this review, we discuss various inflammation-related molecules, especially those altered at the peripheral level, and suggested their potential role as risk factors, diagnostic markers and therapeutic targets in AD. Even though it is ambiguous whether inflammatory cytokines are related to the cause or effect of AD pathogenesis, a better understanding of these molecules during AD pathogenesis can lead to a therapeutic breakthrough against AD.

PRO-INFLAMMATORY CYTOKINES IN AD

IL-1

IL-1 is a pro-inflammatory cytokine, which elicits diverse systemic effects (20). IL-1 was the first cytokine whose actions on the brain were identified (21, 22). The two isoforms of IL-1 were identified as IL-1α and IL-1β encoded by two different genes IL-1A and IL-1B, respectively (23).

Elevated IL-1 was reported not only in acute injuries but also in a number of chronic neurodegenerative disorders (24, 25). IL-1 levels are markedly overexpressed in the brains of patients with AD (26), mainly in microglia (26). Increased IL-1 level is related to Aβ plaque formation, tau phosphorylation, and neurofibrillary tangle formation via activation of MAPK-P38 (27). Also, IL-1 has been reported to modulate neurons in hippocampus (28) and trigger age-related impairment of long-term potentiation (29). In vitro and in vivo experiments demonstrated that the secreted βAPP induced IL-1 overexpression from microglia, which suppressed cholinergic function by enhancing the expression and activity of acetylcholinesterase (AChE) (30), suggesting a possible mechanistic event relevant to cholinergic dysfunction in AD. In a recent report, peripheral changes in blood AChE level were also detected in cognitively normal individuals with cerebral amyloid deposition (31). This phenomenon might be possibly associated with altered cytokine release, including IL-1, during AD pathogenesis. Furthermore, several genetic variants in IL-1 are associated with an increased risk for AD depending on the ethnic groups or ApoE genotypes (32, 33), which reinforce the strong relationship between IL-1 and AD pathogenesis. Additionally, IL-1 interacts with several products of known genetic risk factors for AD, including ApoE, α2-macroglobulin, α1-antichymotrypsin and βAPP (33), suggesting implications for AD pathogenesis.

Increased IL-1β was detected in the blood of patients with AD (7, 3438). Increased levels of both IL-1α and IL-1β have also been reported in the serum of AD patients; however, no changes in cytokine levels were detected in the serum of patients with mild cognitive impairment (MCI), compared with healthy control (39). Further, evidence is not sufficient to suggest that the elevated plasma IL-1 level in AD was caused by peripheral immune activation during AD pathogenesis (35). Instead, the increased levels of circulating IL-1 might be attributed to the central alteration during AD (35). Unfortunately, in other studies, no differences in blood IL-1 levels have been detected between controls and AD patients (4043). Results of blood IL-1 level in MCI are also disputed, suggesting an increase compared with healthy controls in a few studies but not others (37, 39). These contradictory results might be attributed to differences in the sensitivity of diagnostic and screening tools, low levels of IL-1 in the blood or altered IL-1 level in only a subpopulation or specific stage of AD patients.

IL-6

IL-6 levels are elevated in the brains of AD patients (44) and are linked to diffuse plaques representing the early stage of plaque formation (45). Aβ has been shown to induce IL-6 expression in microglia and astrocyte culture system (46). Significant correlations between IL-6 levels in CSF and in matched blood samples were observed (47, 48), and the elevated level of plasma IL-6 was detected in mild cases of AD (48). AD-related increase in blood IL-6 level has been reported in other studies as well (7, 35, 38, 48, 49).

However, other studies failed to show consistent results of increased IL-6 levels in the blood (40, 43, 50, 51), CSF (7, 40, 52, 53) or brain (40). Further, decreased IL-6 levels were reported in serum (54) and in CSF (54, 55) of AD patients. In addition, lipopolysaccharide-induced IL-6 release from blood cells was significantly reduced in moderate AD (36). These conflicting results involving peripheral cytokine levels, including levels of IL-6 and IL-1, dispute the role of cytokines in AD pathogenesis. Nonetheless, reports suggesting the modulation of AD susceptibility based on specific IL-1 or IL-6 gene polymorphism demonstrate the important role played by these cytokines during AD pathogenesis (5658). Especially, specific IL-1 gene polymorphisms are strongly correlated with the increased risk for AD possibly via altered modulation of IL-1-induced neurodegeneration (58).

TNF-α

The pro-inflammatory cytokine tumor necrosis factor (TNF) α is a critical mediator of inflammatory response in diverse tissues and is secreted by diverse cell types including astrocytes and microglia in brain (53). This cytokine is secreted during both acute and chronic systemic inflammation involving immune system and the brain (59).

TNF-α is one of the most well-defined cytokines during AD pathogenesis because TNF-α level is strongly correlated with cognitive decline, neuronal toxicity and cerebral apoptosis. Increased TNF-α levels were found in different anatomic locations of brain in AD patients (60). Also, mild-to-severe AD patients with increased serum TNF-α level showed a 2-fold increase in the rate of cognitive decline and a high baseline TNF-α level was related to a 4-fold increase in cognitive decline (16).

Evidence suggests that the pathological hallmark Aβ induces microglial activation and TNF-α release (61) and this TNF-α-related inflammation plays a deleterious role in neuronal death (62). TNF-α release from microglia, astrocytes and neurons during AD pathogenesis is a chronic event (63) and altered levels of TNF-α in the brain might induce changes in the peripheral levels of TNF-α. Numerous reports suggest evidences for alteration of TNF-α level in biological fluids from AD patients (64). In CSF, an average 25-fold increase of TNF-α level has been reported in AD compared with control (65). In the periphery, the increased levels of blood TNF-α have been widely reported in various studies including MCI and AD patients and were strongly associated with the rate of cognitive decline (7, 16, 43, 6668). Meanwhile, no changes in TNF-α level were reported in another study using serum (42, 53) or CSF (7, 40, 52). Instead, a lower TNF-α level has been reported in the blood of AD patients compared with age-matched control subjects in a study of patients with early-as well as late-onset AD (34). Also, TNF-α release from blood cell following lipopolysaccharide exposure was shown to decrease significantly in moderate AD (36), Probably, the blood TNF-α level may be associated with a wide range of individual variation and reflect disease-dependent alteration (64).

IL-12

IL-12 is a proinflammatory cytokine secreted by activated macrophages, monocytes, and glial cells via Toll-like receptor activation (69, 70) and its dual potential for pro- and anti-inflammation activity has been shown in a previous study (71). During AD pathogenesis, the IL-12 level in CSF is reduced in AD patients compared with neurological control patients (72). Also, another study reported increased IL-12 levels in the blood of patients with mild and moderate AD (7) while severe AD suppressed plasma IL-12 levels (18), which might possibly suggest the potential for dual activities. A recent report demonstrated the inhibition of IL-12/IL-23 pathway via genetic ablation or pharmacological manipulation resulting in a drastic reduction of cerebral amyloid pathology and cognitive deficit (73). Indirect evidence supporting the role of IL-12 during AD pathogenesis is based on Aβ immunization in a mouse model of AD with reduced amyloid burden along with decreased expression of the IL-12Rβ1 receptor in T cells (73, 74). All these results suggest the potential role of IL-12 in neurodegenerative disease including AD.

ANTI-INFLAMMATORY CYTOKINES IN AD

IL-4

IL-4 is an anti-inflammatory cytokine neutralizing the pro-inflammatory action. IL-4 inhibits the secretion of IL-1β, IL-6 and TNF-α by activated monocytes (75). Despite the absence of differences between AD and control subjects in terms of peripheral concentration of IL-4 (7), the blood IL-4 level is closely associated with cognitive decline in AD (17). In this study, AD patients with rapid cognitive decline showed a significant increase in blood IL-4 level compared with those representing a slow decline. More interestingly, the peripheral levels of IL-4 and IL-1β are altered by treatment with acetylcholinesterase inhibitor (AChEI), showing increased IL-4 and decreased IL-1β (76, 77). Recently, it has been reported that AChEI-treated AD patients showed an increase in the peripheral levels of AChE, demonstrating the connection between central AChEI action and peripheral synchronization (31). Therefore, it is possible that the beneficial effects of AChEI treatment in AD patients may not be limited to the central compartment but also mediated via peripheral changes in inflammation mediated by IL-1 via IL-4.

IL-10

IL-10 is an anti-inflammatory cytokine, which reduces inflammation during AD pathogenesis. Increased IL-10 level has been reported in the brains of patients with neurological diseases including Alzheimer’s disease (78) and also in the serum of patients with AD and vascular dementia compared with healthy controls (38) while no change was detected in AD in another study (7, 43). Peripheral IL-10 is another candidate biomarker of disease progression and is strongly associated with clinical status and imaging parameters of disease severity (17). Similar to IL-4, AD patients with increased levels of blood IL-10 exhibit rapid cognitive decline compared with those demonstrating a slow decline (17). Also, the IL-10 level was associated with brain atrophy in MRI measurements during AD (17). Possibly, the anti-inflammatory cytokines, including IL-4 and IL-10, may be regarded as a compensatory mechanism during pathogenesis. A strong compensatory mechanism may imply severe pathological lesions.

THE ROLE OF INTESTINAL CYTOKINES (BRAIN-GUT AXIS) IN AD

Gut microbiota play an important role in host metabolism and physiology and influences not only the immune system but also the nervous system related to brain development and cognitive function (79, 80). Several recent studies have demonstrated the importance of gut microbiota composition in AD pathogenesis and the role of gut microbiota has emerged as the new field in AD-related neurodegeneration (81). Furthermore, microbiota in gut play a key role in peripheral immune cell activation and cytokine secretion during the inflammatory cascade in the periphery and central nervous system-related disruption of gut barrier and blood-brain barrier (81). Therefore, neuroscientists have expanded the scope of studies investigating neuroinflammation in brain to include systemic inflammation involving the brain-gut axis during AD pathogenesis.

The mouse model of AD indicates altered composition of gut microbiota compared with that of healthy wild-type mice, in addition to loss of gut epithelial barrier integrity, chronic systemic and intestinal inflammation (11). A previous study demonstrated that the direct transfer of fecal microbiota from wild-type to AD mouse models ameliorated not only amyloid and tau pathology but also cognitive dysfunction, and the underlying mechanism entailed recovery of intestinal macrophage activity and circulating Ly6C+ monocytes (11). Another study showed that the altered composition of gut microbiota via probiotic formulation in AD mouse models reduced the plasma levels of pro-inflammatory cytokines, IL-1α, IL-1β, IL-2, IL-12, IFNγ and TNF-α, which were higher in AD mouse models compared with levels in healthy wild-type mice (82). Also, probiotic treatment increased the levels of anti-inflammatory cytokines, including IL-4, IL-6, G-CSF, GM-CSF, and downregulated inflammatory cytokines. Partial restoration of impaired neuronal proteolytic pathways and decreased cognitive impairment suggest that inflammation-related cytokines are important modulators of brain gut axis during AD pathogenesis.

POTENTIAL USE OF BLOOD IMMUNE CELLS AS BIOMARKERS FOR AD

Peripheral changes in blood circulation have been known to impact brain function. However, due to the failure of various protein-based circulating blood biomarkers, recent studies investigated cell-based biomarkers. Blood immune cells are potential biomarkers in AD. These white blood cells are classified according to cell lineage (myeloid or lymphoid cells) and are further divided into specific cell types such as T lymphocytes, B lymphocytes, and natural killer cells derived from the common lymphoid progenitor cells, and monocytes, eosinophils, neutrophils, basophils, erythrocytes, mast cells, and thrombocytes originating from common myeloid progenitor cells (83). Accumulating evidence suggests that these immune cells play an important role in AD pathogenesis, for e.g., migration of neutrophils traversing the BBB into the brain targeting amyloid plaques (10), recruitment of monocytes/macrophages via CCL2 or CX3CL1 to the sites of inflammatory response (84), and changes in regulatory T lymphocyte profiles (85) and amyloid-beta peptide autoantibodies from B lymphocytes (86). We discuss the potential immune cell-associated blood biomarkers to provide novel insight into blood-based biomarkers beyond the circulating biomarker candidates reported previously.

Changes in the peripheral profile of blood immune cells

The changes in blood cell profile of AD have yet to be fully investigated; however, several reports showed altered peripheral profile of blood cells in AD. Chen et al. (2017) reported that the blood cell population was associated with AD pathogenesis in 92 AD patients and 84 cognitively normal controls (age and sex matched). The population of lymphocytes and basophils decreased in AD patients compared with normal controls; however, there were no changes in the levels of other white blood cells such as neutrophils, monocytes, and eosinophils (87). Another study reported similar results suggesting that the population of resting regulatory T lymphocytes (Treg) decreased significantly in the AD group compared with that of cognitively normal group (85). Although these studies did not reveal any changes in myeloid cell profile except for basophils, other studies showed an increase in the number of monocytes in the blood (88) and decreased CCR2+ monocytes (89) in AD brain, suggesting that monocytes are possible AD biomarker candidates. Furthermore, Richartz-Salzburger et al. (2007) also reported that T and B lymphocytes are significantly downregulated in subjects with clinically diagnosed AD compared with cognitively normal participants (90). Even if few studies reported the diagnostic sensitivity or specificity of blood immune cell population for AD, the published studies demonstrate the possible role of peripheral immune cells as one of the candidate biomarkers for AD.

COMPLEMENTS AS BIOMARKERS FOR AD

The complement system plays an important role in innate immune response (91) and in the regulation of AD risk factors inducing neuronal death (92). A preponderance of evidence derived from genetic, proteomic, and immunological studies suggests that the system is relevant to AD pathogenesis. Genetic profiles determined using genome-wide association studies (GWAS) reveal the relationship between AD risk and genes associated with the complement cascade, such as single nucleotide polymorphisms (SNP) involving clusterin (CLU) and complement receptor 1 (CR1) (93, 94). C1q and C3 components bind to amyloid beta plaques and activate the classical and alternative complement pathways (92, 95). Previous studies have shown that the levels of complement system components in plasma in AD were altered compared with that of normal controls, such as complement factor H (FH), clusterin, plasma factor I (FI), C4d, iC3b, Bb, and iC3b (9699). Here, we discuss the role of reliable blood-based biomarkers using the complement cascade components.

Genetic profile of the complement system

Emerging evidence derived from genetic studies suggest that the components of the complement cascade are strongly associated with AD pathophysiology (100102). Recent GWAS demonstrated the existence of many SNPs for genes associated with the complement pathway related to AD, such as CLU, CR1, SERPINA3, CRP, C2, CFH, C3, and C4 (91, 102105). Especially, the CLU, also known as apolipoprotein J (ApoJ), and CR1 genes are the major risk genes associated with late-onset AD (LOAD) (102, 106). The three representative SNPs in the Clu gene include rs11136000, rs2279590, and rs9331888 (105). Interestingly, the rs11136000 SNP is observed in Asian and Caucasian populations, and the two populations exhibit similar genetic risk (Asian, OR = 0.85; Caucasian, OR = 0.82) (107, 108). The rs2279590 SNP showed significant correlation with the degree of brain amyloid plaques (109), and the rs9331888 polymorphism is linked to the levels of CLU in blood plasma (110). The CR1 gene, which is mainly expressed in human erythrocytes, encodes CR1 protein to facilitate amyloid-beta clearance mediated via C3b (111). The major polymorphisms of CR1 gene include rs6656401, rs4844609, and rs3818361 (102, 112). Several studies have investigated the specific roles of these SNPs.

Plasma levels of complement cascade-related molecules

Since both CLU and CR1 are the major risk factors involved in AD, they play key roles in neuro-inflammation and innate immunity (91). The relationship between CLU protein and amyloid-beta peptide has been reported, such as the ability of CLU in amyloid beta clearance (113). Blood CLU levels were drastically increased in AD patients compared with cognitively normal controls (114), and similar results were published by another group suggesting that the plasma levels of CLU increased in participants with cognitive decline and in AD patients in longitudinal follow-up, but not in CSF samples (115). Plasma CR1 levels were not related to the clinical diagnosis of AD. However, the levels of rs4844609 and rs6656401 SNP carriers were slightly increased compared with that of CR1 without the SNPs (112, 116). Cerebrospinal fluid (CSF) levels of CR1 also did not show any differences between the different cognitive stages of AD (117). Plasma levels of C3 and C4 were not much in evidence; however, Bennett el al., (2012) showed that the levels of C4a protein were enhanced in AD participants compared with cognitively normal subjects. Thambisetty et al. (2011) reported the association of C3 and C3a protein with brain atrophy in AD subjects (99, 118). Plasma C-reactive protein (CRP) levels are relatively well known, but there have been some contradictory results suggesting the reduced levels of plasma CRP in AD (119). However, other studies suggest higher plasma levels of CRP in AD or subjects with cognitive decline (120122).

CONCLUSION

Here, we discussed a variety of inflammatory mediators such as pro- and anti-inflammatory cytokines, intestinal cytokines, peripheral immune cells, and complement cascade-related molecules (Fig. 1 and Table 1). Reports regarding peripheral cytokine levels show very inconsistent results in various studies. The studies involving IL-1, IL-6 and TNF-α need to be validated using large-scale population cohorts. Recently, a combination of protease and phosphatase inhibitors has been used to detect low levels of blood biomarkers in AD (123). Effective detection of low levels of blood biomarkers might greatly facilitate the detection of low levels of cytokines in the blood. Furthermore, AD pathogenesis can alter diverse physiological systems, including neuronal function, brain structure, immune dynamics, brain-gut axis, and metabolism. Therefore, a single biomarker may not be adequate to delineate the pathophysiology of AD completely. Instead, a combination of multiple markers representing different stage of disease progression is the best strategy. Immune cell profiles and complement cascade play a potential role in providing novel insight into blood-based biomarkers compared with circulating protein biomarkers reported previously, although further validation is needed. Although the use of inflammatory mediators as peripheral AD biomarkers has yet to be established, further studies are needed given the link between inflammation and AD.

ACKNOWLEDGEMENTS

This work was supported by a grant of the Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C0630 and HI19C1132) for I. Mook-Jung and a grant from NRF (NRF-2019R1I1A1A01063525) for S. Han.

CONFLICTS OF INTEREST

The authors have no conflicting interests.

Figure
Fig. 1. Graphical summary of peripheral inflammatory biomarker candidates.
Table

Altered levels of candidate biomarkers

Biomarker (blood)Up regulation (reference no.)Down regulation (reference no.)No regulation (reference no.)Superiority
IL-1(7, 3439)-(4043)Up + No
IL-6(7, 35, 38, 48, 49)(54)(43, 50, 51)Up + No + Down
TNF-α(7, 16, 43, 6668)(34)(42, 53)Up + No + Down
IL-12(7)(18)-Up + Down
IL-4(7)No
IL-10(7, 43)No
Lymphocyte-(85, 90)-Down
Monocyte(88) (89)-(87)Up + No
CLU(114, 115)--Up
CR1--(112, 116)No
C3(99)--Up
C4(118)--Up
CRP(120122)(119)-Up + Down

Biomarker (intestine)Up & Down changes based on probiotic formulation or FMT in AD mouse modelReference no.

IL-1Down(82)
IL-2Down(82)
IL-12Down(82)
IFN-γDown(82)
TNF-αDown(82)
IL-4Up(82)
IL-6Up(82)
G-CSFUp(82)
GM-CSFUp(82)
Ly6C+ monocyteDown(11)

Abbreviations: up, up regulation; down, down regulation; no, no regulation; FMT, fecal microbiota transplant.


References
  1. Heneka MT, Carson MJ, and El Khoury J (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14, 388-405.
    Pubmed KoreaMed CrossRef
  2. Han SH, Park JC, and Mook-Jung I (2016) Amyloid beta-interacting partners in Alzheimer’s disease: From accomplices to possible therapeutic targets. Prog Neurobiol 137, 17-38.
    Pubmed CrossRef
  3. Hansen DV, Hanson JE, and Sheng M (2018) Microglia in Alzheimer’s disease. J Cell Biol 217, 459-472.
    Pubmed KoreaMed CrossRef
  4. Cagnin A, Brooks DJ, and Kennedy AM (2001) In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467.
    Pubmed CrossRef
  5. Baik SH, Kang S, and Lee W (2019) A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer’s Disease. Cell Metab 30, 493-507 e496.
    Pubmed CrossRef
  6. Yasojima K, Schwab C, McGeer EG, and McGeer PL (1999) Up-regulated production and activation of the complement system in Alzheimer’s disease brain. Am J Pathol 154, 927-936.
    Pubmed KoreaMed CrossRef
  7. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, and Herrmann N (2010) A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 68, 930-941.
    Pubmed CrossRef
  8. Correa JD, Starling D, Teixeira AL, Caramelli P, and Silva TA (2011) Chemokines in CSF of Alzheimer’s disease patients. Arq Neuropsiquiatr 69, 455-459.
    CrossRef
  9. Sui X, Liu J, and Yang X (2014) Cerebrospinal fluid biomarkers of Alzheimer’s disease. Neurosci Bull 30, 233-242.
    Pubmed KoreaMed CrossRef
  10. Baik SH, Cha MY, and Hyun YM (2014) Migration of neutrophils targeting amyloid plaques in Alzheimer’s disease mouse model. Neurobiol Aging 35, 1286-1292.
    Pubmed KoreaMed CrossRef
  11. Kim MS, Kim Y, and Choi H (2020) Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut 69, 283-294.
    Pubmed CrossRef
  12. Akiyama H, Barger S, and Barnum S (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21, 383-421.
    Pubmed KoreaMed CrossRef
  13. Wilson CJ, Finch CE, and Cohen HJ (2002) Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50, 2041-2056.
    Pubmed CrossRef
  14. Solfrizzi V, D’Introno A, and Colacicco AM (2006) Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364, 91-112.
    Pubmed CrossRef
  15. Metcalfe MJ, and Figueiredo-Pereira ME (2010) Relationship between tau pathology and neuroinflammation in Alzheimer’s disease. Mt Sinai J Med 77, 50-58.
    Pubmed KoreaMed CrossRef
  16. Holmes C, Cunningham C, and Zotova E (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774.
    Pubmed KoreaMed CrossRef
  17. Leung R, Proitsi P, and Simmons A (2013) Inflammatory proteins in plasma are associated with severity of Alzheimer’s disease. PLoS One 8, e64971.
    Pubmed KoreaMed CrossRef
  18. Motta M, Imbesi R, Di Rosa M, Stivala F, and Malaguarnera L (2007) Altered plasma cytokine levels in Alzheimer’s disease: correlation with the disease progression. Immunol Lett 114, 46-51.
    Pubmed CrossRef
  19. Dionisio-Santos DA, Olschowka JA, and O’Banion MK (2019) Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease. J Neuroinflammation 16, 74.
    Pubmed KoreaMed CrossRef
  20. Dinarello CA, and Wolff SM (1993) The role of interleukin-1 in disease. N Engl J Med 328, 106-113.
    Pubmed CrossRef
  21. Besedovsky H, del Rey A, Sorkin E, and Dinarello CA (1986) Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233, 652-654.
    Pubmed CrossRef
  22. Shaftel SS, Griffin WS, and O’Banion MK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5, 7.
    Pubmed KoreaMed CrossRef
  23. Nicklin MJ, Weith A, and Duff GW (1994) A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 19, 382-384.
    Pubmed CrossRef
  24. Allan SM, Tyrrell PJ, and Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5, 629-640.
    Pubmed CrossRef
  25. Patel HC, Boutin H, and Allan SM (2003) Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 992, 39-47.
    Pubmed CrossRef
  26. Griffin WS, Stanley LC, and Ling C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86, 7611-7615.
    Pubmed KoreaMed CrossRef
  27. Sheng JG, Jones RA, and Zhou XQ (2001) Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer’s disease: potential significance for tau protein phosphorylation. Neurochem Int 39, 341-348.
    Pubmed KoreaMed CrossRef
  28. Schneider H, Pitossi F, Balschun D, Wagner A, del Rey A, and Besedovsky HO (1998) A neuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci U S A 95, 7778-7783.
    Pubmed KoreaMed CrossRef
  29. Murray CA, and Lynch MA (1998) Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci 18, 2974-2981.
    Pubmed KoreaMed CrossRef
  30. Li Y, Liu L, and Kang J (2000) Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 20, 149-155.
    Pubmed KoreaMed CrossRef
  31. Han SH, Park JC, and Byun MS (2019) Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. Neurobiol Aging 73, 21-29.
    Pubmed CrossRef
  32. Su F, Bai F, and Zhang Z (2016) Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms. Neurosci Bull 32, 469-480.
    Pubmed KoreaMed CrossRef
  33. Mrak RE, and Griffin WS (2000) Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol 59, 471-476.
    Pubmed KoreaMed CrossRef
  34. Alvarez XA, Franco A, Fernandez-Novoa L, and Cacabelos R (1996) Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 29, 237-252.
    Pubmed CrossRef
  35. Licastro F, Pedrini S, and Caputo L (2000) Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain?. J Neuroimmunol 103, 97-102.
    Pubmed CrossRef
  36. De Luigi A, Pizzimenti S, and Quadri P (2002) Peripheral inflammatory response in Alzheimer’s disease and multiinfarct dementia. Neurobiol Dis 11, 308-314.
    Pubmed CrossRef
  37. Forlenza OV, Diniz BS, and Talib LL (2009) Increased serum IL-1beta level in Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28, 507-512.
    Pubmed CrossRef
  38. Angelopoulos P, Agouridaki H, and Vaiopoulos H (2008) Cytokines in Alzheimer’s disease and vascular dementia. Int J Neurosci 118, 1659-1672.
    Pubmed CrossRef
  39. Italiani P, Puxeddu I, and Napoletano S (2018) Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression?. J Neuroinflammation 15, 342.
    Pubmed KoreaMed CrossRef
  40. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, and Smith AD (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12, 215-227.
    Pubmed CrossRef
  41. Pirttila T, Mehta PD, Frey H, and Wisniewski HM (1994) Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer’s disease. Neurobiol Aging 15, 313-317.
    Pubmed CrossRef
  42. Yasutake C, Kuroda K, Yanagawa T, Okamura T, and Yoneda H (2006) Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer’s disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 256, 402-406.
    Pubmed CrossRef
  43. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, and Baloyannis S (2008) Systemic immune aberrations in Alzheimer’s disease patients. J Neuroimmunol 193, 183-187.
    CrossRef
  44. Bauer J, Strauss S, and Schreiter-Gasser U (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 285, 111-114.
    Pubmed CrossRef
  45. Huell M, Strauss S, Volk B, Berger M, and Bauer J (1995) Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer’s disease patients. Acta Neuropathol 89, 544-551.
    Pubmed CrossRef
  46. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, and Hong CH (2009) Peripheral cytokines and chemokines in Alzheimer’s disease. Dement Geriatr Cogn Disord 28, 281-287.
    CrossRef
  47. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, and Janciauskiene S (2003) Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 16, 136-144.
    Pubmed CrossRef
  48. Wu YY, Hsu JL, Wang HC, Wu SJ, Hong CJ, and Cheng IH (2015) Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer’s Disease. Dement Geriatr Cogn Dis Extra 5, 424-434.
    Pubmed KoreaMed CrossRef
  49. Singh VK, and Guthikonda P (1997) Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 31, 657-660.
    CrossRef
  50. Angelis P, Scharf S, Mander A, Vajda F, and Christophidis N (1998) Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer’s disease. Neurosci Lett 244, 106-108.
    Pubmed CrossRef
  51. van Duijn CM, Hofman A, and Nagelkerken L (1990) Serum levels of interleukin-6 are not elevated in patients with Alzheimer’s disease. Neurosci Lett 108, 350-354.
    Pubmed CrossRef
  52. Garlind A, Brauner A, Hojeberg B, Basun H, and Schultzberg M (1999) Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer’s disease patients. Brain Res 826, 112-116.
    Pubmed CrossRef
  53. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, and Blennow K (2003) Cerebral pattern of pro-and anti-inflammatory cytokines in dementias. Brain Res Bull 61, 255-260.
    Pubmed CrossRef
  54. Richartz E, Stransky E, and Batra A (2005) Decline of immune responsiveness: a pathogenetic factor in Alzheimer’s disease?. J Psychiatr Res 39, 535-543.
    Pubmed CrossRef
  55. Yamada K, Furusawa S, and Saito K (1995) Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 9, 10-14.
    Pubmed
  56. Papassotiropoulos A, Bagli M, and Jessen F (1999) A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol 45, 666-668.
    Pubmed CrossRef
  57. Grimaldi LM, Casadei VM, and Ferri C (2000) Association of early-onset Alzheimer’s disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47, 361-365.
    Pubmed CrossRef
  58. Nicoll JA, Mrak RE, and Graham DI (2000) Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 47, 365-368.
    Pubmed KoreaMed CrossRef
  59. Perry VH, Cunningham C, and Holmes C (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7, 161-167.
    Pubmed CrossRef
  60. Zhao M, Cribbs DH, and Anderson AJ (2003) The induction of the TNFalpha death domain signaling pathway in Alzheimer’s disease brain. Neurochem Res 28, 307-318.
    Pubmed CrossRef
  61. Lue LF, Walker DG, and Rogers J (2001) Modeling microglial activation in Alzheimer’s disease with human postmortem microglial cultures. Neurobiol Aging 22, 945-956.
    Pubmed CrossRef
  62. Janelsins MC, Mastrangelo MA, and Park KM (2008) Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 173, 1768-1782.
    Pubmed KoreaMed CrossRef
  63. McAlpine FE, and Tansey MG (2008) Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease. J Inflamm Res 1, 29-39.
    Pubmed KoreaMed CrossRef
  64. Brosseron F, Krauthausen M, Kummer M, and Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: a comparative overview. Mol Neurobiol 50, 534-544.
    Pubmed KoreaMed CrossRef
  65. Tarkowski E, Blennow K, Wallin A, and Tarkowski A (1999) Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19, 223-230.
    Pubmed CrossRef
  66. Magaki S, Mueller C, Dickson C, and Kirsch W (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42, 233-240.
    Pubmed KoreaMed CrossRef
  67. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, and Pedersen BK (1999) A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 54, M357-364.
    Pubmed CrossRef
  68. Fillit H, Ding WH, and Buee L (1991) Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci Lett 129, 318-320.
    Pubmed CrossRef
  69. Aliberti J, Reis e Sousa C, and Schito M (2000) CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 1, 83-87.
    Pubmed CrossRef
  70. Schulz O, Edwards AD, and Schito M (2000) CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13, 453-462.
    Pubmed CrossRef
  71. Chang HD, and Radbruch A (2007) The pro- and anti-inflammatory potential of interleukin-12. Ann N Y Acad Sci 1109, 40-46.
    Pubmed CrossRef
  72. Rentzos M, Paraskevas GP, and Kapaki E (2006) Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. J Neurol Sci 249, 110-114.
    Pubmed CrossRef
  73. Vom Berg J, Prokop S, and Miller KR (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 18, 1812-1819.
    Pubmed CrossRef
  74. Town T, Vendrame M, and Patel A (2002) Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer’s beta-amyloid(1-42). J Neuroimmunol 132, 49-59.
    Pubmed CrossRef
  75. te Velde AA, Huijbens RJ, Heije K, de Vries JE, and Figdor CG (1990) Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood 76, 1392-1397.
    Pubmed CrossRef
  76. Gambi F, Reale M, and Iarlori C (2004) Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol 24, 314-321.
    Pubmed CrossRef
  77. Lugaresi A, Di Iorio A, and Iarlori C (2004) IL-4 in vitro production is upregulated in Alzheimer’s disease patients treated with acetylcholinesterase inhibitors. Exp Gerontol 39, 653-657.
    Pubmed CrossRef
  78. Strle K, Zhou JH, and Shen WH (2001) Interleukin-10 in the brain. Crit Rev Immunol 21, 427-449.
    CrossRef
  79. Fung TC, Olson CA, and Hsiao EY (2017) Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 20, 145-155.
    Pubmed KoreaMed CrossRef
  80. Kau AL, Ahern PP, Griffin NW, Goodman AL, and Gordon JI (2011) Human nutrition, the gut microbiome and the immune system. Nature 474, 327-336.
    Pubmed KoreaMed CrossRef
  81. Kowalski K, and Mulak A (2019) Brain-Gut-Microbiota Axis in Alzheimer’s Disease. J Neurogastroenterol Motil 25, 48-60.
    Pubmed KoreaMed CrossRef
  82. Bonfili L, Cecarini V, and Berardi S (2017) Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep 7, 2426.
    CrossRef
  83. Arosio B, D‘Addario C, and Gussago C (2014) Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. Biomed Res Int 2014.
    Pubmed KoreaMed CrossRef
  84. Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 81, 584-592.
    Pubmed CrossRef
  85. Ciccocioppo F, Lanuti P, and Pierdomenico L (2019) The Characterization of Regulatory T-Cell Profiles in Alzheimer’s Disease and Multiple Sclerosis. Sci Rep 9, 8788.
    CrossRef
  86. Rezai-Zadeh K, Gate D, Szekely CA, and Town T (2009) Can peripheral leukocytes be used as Alzheimer’s disease biomarkers?. Expert Rev Neurother 9, 1623-1633.
    Pubmed KoreaMed CrossRef
  87. Chen SH, Bu XL, and Jin WS (2017) Altered peripheral profile of blood cells in Alzheimer disease: A hospital-based case-control study. Medicine (Baltimore) 96, e6843.
    Pubmed KoreaMed CrossRef
  88. Lunnon K, Ibrahim Z, and Proitsi P (2012) Mitochondrial dysfunction and immune activation are detectable in early Alzheimer’s disease blood. J Alzheimers Dis 30, 685-710.
    Pubmed CrossRef
  89. Naert G, and Rivest S (2013) A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease. J Mol Cell Biol 5, 284-293.
    Pubmed CrossRef
  90. Richartz-Salzburger E, Batra A, and Stransky E (2007) Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res 41, 174-178.
    CrossRef
  91. Aiyaz M, Lupton MK, Proitsi P, Powell JF, and Lovestone S (2012) Complement activation as a biomarker for Alzheimer’s disease. Immunobiology 217, 204-215.
    CrossRef
  92. Kolev MV, Ruseva MM, Harris CL, Morgan BP, and Donev RM (2009) Implication of complement system and its regulators in Alzheimer’s disease. Curr Neuropharmacol 7, 1-8.
    Pubmed KoreaMed CrossRef
  93. Kamboh MI, Demirci FY, and Wang X (2012) Genome-wide association study of Alzheimer’s disease. Transl Psychiatry 2, e117.
    CrossRef
  94. Kok EH, Luoto T, Haikonen S, Goebeler S, Haapasalo H, and Karhunen PJ (2011) CLU, CR1 and PICALM genes associate with Alzheimer’s-related senile plaques. Alzheimers Res Ther 3, 12.
    Pubmed KoreaMed CrossRef
  95. Bradt BM, Kolb WP, and Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med 188, 431-438.
    Pubmed KoreaMed CrossRef
  96. Hakobyan S, Harding K, and Aiyaz M (2016) Complement Biomarkers as Predictors of Disease Progression in Alzheimer’s Disease. J Alzheimers Dis 54, 707-716.
    Pubmed CrossRef
  97. Weinstein G, Beiser AS, and Preis SR (2016) Plasma clusterin levels and risk of dementia, Alzheimer’s disease, and stroke. Alzheimers Dement (Amst) 3, 103-109.
    Pubmed KoreaMed CrossRef
  98. Williams MA, Haughton D, Stevenson M, Craig D, Passmore AP, and Silvestri G (2015) Plasma Complement factor H in Alzheimer’s Disease. J Alzheimers Dis 45, 369-372.
    CrossRef
  99. Thambisetty M, Simmons A, and Hye A (2011) Plasma biomarkers of brain atrophy in Alzheimer’s disease. PLoS One 6, e28527.
    CrossRef
  100. Haure-Mirande JV, Wang M, and Audrain M (2019) Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in cerebral Abeta amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Abeta burden. Mol Psychiatry 24, 431-446.
    CrossRef
  101. Efthymiou AG, and Goate AM (2017) Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener 12, 43.
    Pubmed KoreaMed CrossRef
  102. Lambert JC, Heath S, and Even G (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41, 1094-1099.
    Pubmed CrossRef
  103. Belbin O, Dunn JL, and Chappell S (2008) A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD. Neurobiol Aging 29, 1167-1176.
    Pubmed CrossRef
  104. Toral-Rios D, Franco-Bocanegra D, and Rosas-Carrasco O (2015) Evaluation of inflammation-related genes polymorphisms in Mexican with Alzheimer’s disease: a pilot study. Front Cell Neurosci 9, 148.
    Pubmed KoreaMed CrossRef
  105. Morgan BP (2018) Complement in the pathogenesis of Alzheimer’s disease. Semin Immunopathol 40, 113-124.
    CrossRef
  106. Jin C, Li W, Yuan J, Xu W, and Cheng Z (2012) Association of the CR1 polymorphism with late-onset Alzheimer’s disease in Chinese Han populations: a meta-analysis. Neurosci Lett 527, 46-49.
    Pubmed CrossRef
  107. Liu G, Wang H, and Liu J (2014) The CLU gene rs11136000 variant is significantly associated with Alzheimer’s disease in Caucasian and Asian populations. Neuromolecular Med 16, 52-60.
    Pubmed CrossRef
  108. Zhu R, Liu X, and He Z (2018) Association between CLU gene rs11136000 polymorphism and Alzheimer’s disease: an updated meta-analysis. Neurol Sci 39, 679-689.
    Pubmed CrossRef
  109. Tan L, Wang HF, and Tan MS (2016) Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. Sci Rep 6, 26027.
    Pubmed KoreaMed CrossRef
  110. Xing YY, Yu JT, and Cui WZ (2012) Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer’s disease. J Alzheimers Dis 29, 515-519.
    Pubmed CrossRef
  111. Zhou J, Fonseca MI, Pisalyaput K, and Tenner AJ (2008) Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease. J Neurochem 106, 2080-2092.
    Pubmed KoreaMed CrossRef
  112. Fonseca MI, Chu S, and Pierce AL (2016) Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function. PLoS One 11, e0149792.
    Pubmed KoreaMed CrossRef
  113. Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, and Buckley NJ (2019) Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci 13, 164.
    Pubmed KoreaMed CrossRef
  114. Thambisetty M, Simmons A, and Velayudhan L (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
    Pubmed KoreaMed CrossRef
  115. Jongbloed W, van Dijk KD, and Mulder SD (2015) Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease. J Alzheimers Dis 46, 1103-1110.
    Pubmed CrossRef
  116. Winston CN, Goetzl EJ, Schwartz JB, Elahi FM, and Rissman RA (2019) Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer’s disease dementia. Alzheimers Dement (Amst) 11, 61-66.
    Pubmed KoreaMed CrossRef
  117. Daborg J, Andreasson U, and Pekna M (2012) Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease. J Neural Transm (Vienna) 119, 789-797.
    Pubmed CrossRef
  118. Bennett S, Grant M, and Creese AJ (2012) Plasma levels of complement 4a protein are increased in Alzheimer’s disease. Alzheimer Dis Assoc Disord 26, 329-334.
    CrossRef
  119. Yarchoan M, Louneva N, and Xie SX (2013) Association of plasma C-reactive protein levels with the diagnosis of Alzheimer’s disease. J Neurol Sci 333, 9-12.
    Pubmed KoreaMed CrossRef
  120. Locascio JJ, Fukumoto H, and Yap L (2008) Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65, 776-785.
    Pubmed KoreaMed CrossRef
  121. Watanabe Y, Kitamura K, and Nakamura K (2016) Elevated C-Reactive Protein Is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST). Dement Geriatr Cogn Dis Extra 6, 10-19.
    Pubmed KoreaMed CrossRef
  122. Vintimilla R, Hall J, Johnson L, and O‘Bryant S (2019) The relationship of CRP and cognition in cognitively normal older Mexican Americans: A cross-sectional study of the HABLE cohort. Medicine (Baltimore) 98, e15605.
    Pubmed KoreaMed CrossRef
  123. Park JC, Han SH, and Cho HJ (2017) Chemically treated plasma Abeta is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res Ther 9, 20.
    Pubmed KoreaMed CrossRef


This Article


Cited By Articles
  • CrossRef (0)

Funding Information

Collections

Services
Social Network Service

e-submission

Archives